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Abstract
High-risk human papilloma virus (HR-HPV) has increasingly been associated with head and neck squamous cell carcinoma 
(HNSCC), in particular oropharyngeal cancers. Ezrin–Radixin–Moesin Binding Phosphoprotein 50 (EBP50), a putative 
tumour suppressor, localises to the plasma membrane in suprabasal epithelium and to the cytoplasm in proliferative basal 
layers, and is a target for degradation by the HR-HPV E6 oncoprotein. The aim of this study was to investigate EBP50 pro-
tein expression patterns in HNSCC in a large Scottish cohort to determine if there was a correlation with HPV status and 
clinical outcomes. EBP50 expression patterns were assessed in 156 HNSCC including oropharyngeal (37.8%), laryngeal 
(24%), oral (19%) and other sites (18.5%), which were genotyped for presence of HR-HPV. HNSCC were generally negative 
for membranous EBP50. EBP50 expression was either cytoplasmic/absent, being ‘predominantly cytoplasmic’ in 76 (49%), 
‘weak/negligible cytoplasmic’ in 44 (28%), ‘strongly cytoplasmic’ in 5 (3%), ‘heterogeneous’ in 26 (17%) and ‘other’ in 5 
(3%) samples. Forty tumours (25%) were positive for HPV DNA, predominantly HR-HPV 16, and 44 (28%) were p16 posi-
tive. The majority of tumours (71%) with ‘weak/negligible cytoplasmic’ EBP50 expression originated in the oropharynx 
were more likely to have positive neck nodes, overexpression of p16 and positive tumour HR-HPV status (P < 0.001). Dif-
ferences in EBP50 levels between oropharyngeal and non-oropharyngeal tumours may be linked to degradation of EBP50 
by HR-HPV, and loss of EBP50 may therefore be a surrogate biomarker for HR-HPV infection in oropharyngeal tumours.
Keywords EBP50 · Head and neck squamous cell carcinoma · Human papilloma virus · Oropharyngeal cancers
Introduction
In 2014, there were 11,400 new cases of head and neck 
squamous cell carcinoma (HNSCC) in the United Kingdom 
and over the last decade, incidence rates have increased by 
almost a quarter [1]. Despite improvements in treatment, 
almost half the affected patients will not survive 5 years and 
mortality rates are set to rise to seven deaths per 100,000 
people by 2035 [1]. While smoking and alcohol are the 
biggest risk factors, high-risk human papilloma virus (HR-
HPV) is implicated in the increasing rates of oropharyngeal 
cancer [2].
Ezrin–Radixin–Moesin (ERM) Binding Phosphoprotein 
50 (EBP50), a PDZ (postsynaptic density 95, PSD-85; discs 
large, Dlg; zonula occludens-1, ZO-1) domain scaffolding 
protein, also known as  Na+/H+ exchanger 3 regulatory factor 
1 (NHERF1), is found in abundance at the plasma mem-
branes of polarised epithelial cells where it regulates tissue 
architecture and cell migration. It functions as a molecular 
scaffold, promoting the assembly of macromolecular signal-
ling protein complexes at the plasma membrane of epithe-
lial cells, thereby regulating their activity. Major signalling 
pathways regulated by EBP50 include Phosphatidylinositol-
3-OH kinase (PI-3K)/AKT/Phosphatase and tensin homo-
logue (PTEN) pathway, platelet derived growth factor recep-
tor (PDGFR), epidermal growth factor receptor (EGFR) and 
Wnt/β-catenin signalling [3].
Increasingly, while EBP50 is being reported as a potential 
player in cancer, its precise role is controversial [3]. Under 
physiological conditions, EBP50 localises to the apical 
membrane of polarised epithelial cells where it stabilises 
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transmembrane receptors and junctional complexes [3]. In 
contrast, in numerous malignant tumours including breast, 
colorectal and hepatocellular carcinoma, aberrant EBP50 
expression (either overexpressed, altered subcellular locali-
sation or loss) has been observed [4–6]. These expression 
patterns led to the speculation that the function of EBP50 
may be dependent on its subcellular location, whereby it acts 
as a tumour suppressor at the plasma membrane or acts as an 
oncogene when relocalised to the cytoplasm or its expres-
sion is lost [3]. Indeed, there is evidence for both, with cyto-
plasmic or membranous EBP50 reported to interfere with 
specific signalling pathways that either promote or suppress 
tumourigenesis respectively [3–5, 7, 8].
EBP50 is a known target for degradation by the HR-HPV 
type 16 E6 oncoprotein [9], which contributes to carcinogen-
esis by disrupting multiple cellular pathways [10]. HPV16 is 
linked to cervical cancer development [11], and EBP50 has 
been shown to be downregulated in HPV16-positive cervi-
cal premalignant lesions and in cervical cancer-derived cell 
lines, concomitant with EGFR activation [12].
Oropharyngeal squamous cell carcinoma (OPSCC) is 
among the cancers with the fastest increasing incidence in 
Scotland [13] and the United States [14]. A recent United 
Kingdom study reported that 51.8% of these cancers were 
HPV-positive [15]. At other head and neck sites, however, 
HPV is not thought to be causative [16].
The aim of this study was to investigate EBP50 protein 
expression patterns protein in HNSCC in a large Scottish 
cohort, to determine if there was a correlation with HPV 
DNA status and clinical outcomes.
Materials and Methods
This retrospective study, approved by the Tayside Tissue 
Bank (TR000325), was conducted according to the guide-
lines outlined by the Research Governance Framework in 
Tayside, Scotland. Patients with HNSCC treated between 
January 2006 and December 2011 were selected from a sin-
gle centre secondary care hospital. The inclusion criteria 
were patients over the age of 18 years diagnosed with a new 
primary HNSCC with adequate tissue available to allow 
immunohistochemistry (p16, EBP50) and PCR (HPV). The 
exclusion criteria included patients under 18 years of age, 
recurrent HNSCC, cases lost to follow up and inadequate 
quantity/quality of tissue for downstream processing.
The most widely used assay to detect the presence of tran-
scriptionally active HPV in HNSCC is to determine the p16 
status of tissue specimens by immunohistochemistry [17]. 
At this time all oropharyngeal cases had p16 staining car-
ried out as part of the routine pathology reporting of cases 
in Tayside. A request was made for the tumours for the other 
head and neck sites to also have p16 staining. Slides stained 
for p16 were analysed by a single pathologist and scored as 
p16 positive if strong diffuse nuclear and cytoplasmic stain-
ing was observed in ≥ 70% of the tumour, consistent with 
the reporting protocol within Tayside [18]. Normal tonsillar 
tissue was used as a control.
Survival data and clinical information were recorded 
by reviewing case notes. Survival outcomes were assessed 
against p16 status, smoking and alcohol history, disease 
stage, HPV status and EBP50 expression. A completed data-
base was transferred to Tayside Health Informatics Centre 
(HIC) for anonymisation via a secure NHS transfer system.
Immunohistochemistry
Coupes (5 μm) of formalin fixed paraffin embedded (FFPE) 
archival tissue were de-paraffinised in xylene, and re-
hydrated in graded ethanol solutions (100, 90, 70%). The 
sections were rinsed with  dH2O before microwave antigen 
retrieval in 10 mM citrate buffer (pH 6.4) for 15 min. Endog-
enous peroxidase activity was blocked with 10% hydrogen 
peroxide. After rinsing, staining was performed using the 
Vectastain Elite ABC kit according to the manufacturer 
(Vector Labs). Briefly, the slides were blocked with normal 
goat serum [20 min, 1% BSA/PBS (w/v)], before incubat-
ing with primary EBP50 rabbit antibody (PA1-090, Thermo 
Fisher Scientific, 1:2000, 1% BSA/PBS (w/v), 30 min). After 
washing and incubating with biotinylated secondary anti-
body (1:200, 1% BSA/PBS (w/v), 30 min) the slides were 
incubated with Vectastain ABC reagent. After rinsing, the 
sections were developed in peroxidase substrate solution 
(5–8 min), rinsed in water, counterstained with haematoxy-
lin, dehydrated in graded ethanol solutions (70, 90, 100%) 
and cleared in xylene. Tissue sections were mounted with 
DePeX mounting medium before visualising under a light 
microscope.
Quantification of EBP50 Staining
The protocol for scoring of EBP50 immunohistochemistry 
was adapted from Lv et al. [19]. Sections were analysed by 
two independent observers (AS and DHC) blinded to the 
sample identities. Additionally, 10% of the sections were 
scored by a third independent observer (MM). Differences in 
inter-observer scores (3 out of 156 tumours, < 2%) were rec-
onciled by re-reviewing sections. Five random representative 
fields (100 cells each) were viewed using ×40 magnification. 
Membrane and cytoplasmic EBP50 expression patterns were 
scored separately as shown in Table 1.
DNA Extraction
Tissue section curls (3–5) (5–10 µm) were used for prep-
aration of genomic DNA using the QIAamp DNA FFPE 
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Tissue kit according to the manufacturer’s instructions. 
Briefly, paraffin was removed with xylene and ethanol. After 
resuspension in Buffer ATL, the cell pellet was treated with 
Proteinase K (56 °C, 1 h, then 90 °C, 1 h). After ethanol 
precipitation, DNA was collected on a QIAamp MinElute 
column before elution in Buffer ATE. Purified DNA samples 
were stored at − 20 °C.
HPV Genotyping of Tumour Samples
HPV DNA was detected by conventional PCR. Consensus 
primers specific to the β-globin gene and L1, E1 and E7 
genes of the HPV virus were used. All β-globin-positive 
samples were initially subject to PCR with L1 primers. As 
the L1 open reading frame may be disrupted as a result of 
viral integration, L1-negative samples were also subject to 
PCR using E1 primers. To determine specific HPV isoforms, 
primers to the E7 genes of HPV16, 18, 33 and 52 were used 
[20–23]. Specificity was determined on template DNA from 
SiHa (HPV18) and HeLa (HPV16) cell lines, and plasmids 
containing HPV33 and HPV52 (gifts from Dr. G. Orth and 
Dr. W. Lancaster, International HPV Reference Centre, 
Karolinska Institutet, Stockholm).
PCR was carried out with template DNA (100 ng), for-
ward and reverse primers (0.4 µM), MyTaq DNA Polymer-
ase (0.5 µl) in 50 µl. Denatured DNA (94 °C, 3 min) was 
subject to 35 cycles of PCR (94 °C for 15 s, primer anneal-
ing between 50 and 58 °C for 15 s, 72 °C for 15 s), with a 
final elongation step of 72 °C for 5 min.
Confirmation of HPV Genotypes by DNA Sequencing
PCR products were purified using the QIAquick Gel Extrac-
tion Kit. Briefly, DNA fragments were excised from the aga-
rose gel, solubilised with Buffer QG (50 °C, 10 min) before 
isopropanol precipitation. DNA was collected on a QIAquick 
spin column before eluting with  dH20. PCR products were 
sequenced by the Tayside Centre for Genomic Analysis, 
Ninewells Hospital. PCR products (5 µl) were purified using 
a modification of the ExoSAP method by incubating with 
exonuclease I (1 U) and shrimp alkaline phosphatase (1 U) 
for 20 min at 37 °C before inactivation at 80 °C for 15 min. 
Samples were sequenced bidirectionally using the ABI Big-
Dye Terminator version 3.1 cycle sequencing kit (Applied 
Biosystems) and analysed on the Applied Biosystems 3730 
DNA Analyser (Applied Biosystems). Sequence analysis 
was performed using MacVector version 12.03 (MacVector 
Inc., Waterbeach, Cambridge, UK).
Statistical Analysis
Data was analysed using SPSS (IBM Statistics Version 22). 
Data related to categorical variables was described in terms 
of number of patients (percentages) and as mean or median 
for continuous variables. Chi-squared test of independence 
was used to report on pairwise correlation between p16 sta-
tus, HPV status and EBP50 expression on the one hand and 
social demographics and clinical/histopathological charac-
teristics of the cohort on the other. Statistical significance 
was defined as p < 0.05. Overall survival (OS) was defined 
as time (months) from diagnosis to death, end of study or 
date of last follow-up. Recurrence free survival (RFS) was 
defined as time (months) from diagnosis to locoregional 
recurrence. Disease free survival (DFS) was defined as time 
(months) from diagnosis to death due to head and neck can-
cer. Kaplan–Meier analysis was used to obtain 2- and 5-year 
survival curves. The Cox Proportional hazards model was 
used to estimate Hazard Ratio (HR) and 95% Confidence 
Interval (CI) for prognostic significance of single and multi-
ple variables. The Likelihood Ratio test was used to compare 
the relative strength of p16 and EBP50 expression as indica-
tors of HPV infection.
Results
Given the heterogeneous nature of the cohort, we undertook 
immunohistochemistry of FFPE stratified squamous epithe-
lium of tonsil tissue and normal oral mucosa to establish the 
baseline pattern of EBP50 staining in the various normal 
Table 1  Quantification of 
immunohistochemical EBP50 
staining Reproduced with 
permission from Lv et al. [19]
Five random representative fields of 100 cells each were viewed using ×40 magnification, and each tumour 
allocated a staining pattern for EBP50 after quantification by two independent observers (AS, DHC). A 
third independent observer (MM) scored 10% of the samples
Membrane staining
 Negative No staining in > 10% of the tumour cells
 Positive Weak or moderate staining in > 10% of the tumour cells
 Mixed Combination of the above
Cytoplasmic staining
 Negligible/weak Negligible/weak staining in > 10% of the tumour cells
 Positive Moderate staining in > 10% of the tumour cells
 Mixed Combinations of the above
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oral epithelia. Although EBP50 staining differed in the dif-
ferent layers of tonsil tissue (Fig. 1A (b)) and normal oral 
mucosa (Fig. 1B (b)), the staining pattern was consistent 
between the two tissue types. Whilst EBP50 was predomi-
nantly membranous in the suprabasal layers (Fig. 1A, B (c)) 
(stratum spinosum, stratum granulosum), no immunoreac-
tivity was detected in the stratum corneum. Moving deeper 
from the suprabasal to the stratum basale, EBP50 staining 
changed from the membrane to a predominantly cytoplasmic 
location (Fig. 1A, B (d)), which correlated with prolifera-
tive basal layers. No nuclear EBP50 immunoreactivity was 
detected, and antibody specificity confirmed by blocking 
with recombinant GST-EBP50 protein (data not shown).
Having established the baseline EBP50 staining in oral 
tissue, a cohort of 156 samples from predominantly male 
patients (68%) with a mean age of 65 years (range 30–90) 
Fig. 1  Differential localisation 
of EBP50 in stratified squamous 
epithelium of A tonsil tissue and 
B normal oral mucosa. Immu-
nohistochemical analysis of oral 
tissue sections stained with a 
No primary antibody and b anti-
EBP50 antibody (1:2000), and 
counterstained with haematoxy-
lin. c and d are expanded sec-
tions of (b) showing suprabasal 
(stratum spinosum, stratum 
granulosum) and basal layers 
(stratum basale), with mem-
brane-bound and cytoplasmic 
EBP50 respectively. Little or 
no EBP50 staining was visible 
in the outer stratum corneum. 
Magnification ×100
Head and Neck Pathology 
1 3
were selected. The mean length of follow up i.e. the date 
of diagnosis to the date of last follow up or the end of the 
study period of the date of death was 39 months, with 75% 
of patients followed up for 60 months. Treatment was sur-
gery (19%), radiotherapy (25%), surgery and post-operative 
radiotherapy (11%), multimodality treatment (35%), pallia-
tion (8%) and data missing (2%). The tumour sites were oro-
pharyngeal (37.8%), laryngeal (24%), oral (19%) and other 
sites (unknown primaries, nares, nasopharyngeal) (18.5%). 
Approximately half the patients presented with stage IV dis-
ease (48%). Recurrence was observed in 16% of cases and 
the OS was 50.6%.
EBP50 expression within the tumour cohort, quantified as 
described in Table 1, is summarised in Table 2, with repre-
sentative immunohistochemical examples of patterns found 
in the majority of HNSCC shown in Fig. 2. The majority of 
tumours had cytoplasmic EBP50, the breakdown of which 
was ‘predominantly cytoplasmic’ in 76 (49%) samples 
(Fig. 2b, c), ‘weak/negligible cytoplasmic’ in 44 (28%) sam-
ples (Fig. 2d, e) and ‘strongly cytoplasmic’ in 5 (3%) of sam-
ples. ‘Heterogeneous’ staining, where cytoplasmic EBP50 
varied across a tumour (negative to positive), occasionally 
with some sparse membrane staining, was seen in 26 (17%) 
samples. Five samples (3%) had traces of membranous stain-
ing within a cytoplasmic EBP50 background. In general, 
with the exception of a few samples, HNSCC specimens 
were immunonegative for membranous EBP50 (Table 2). 
The lack of EBP50 expression at the plasma membrane of 
tumour cells (Fig. 2b, c) is consistent with the EBP50 stain-
ing in the stratum basale in normal tissue (Fig. 1). Together, 
these data are consistent with cytoplasmic or low levels of 
EBP50 being specifically associated with proliferative tis-
sues, both normal and tumour in origin.
The clinical and pathological characteristics of the 
study subset were analysed based on EBP50 expression 
patterns (Table 3), where we found a significant associa-
tion with smoking status and disease. ‘Weak/negligible 
cytoplasmic’ EBP50 expression significantly correlated 
with non- or ex-smokers (p = 0.019), late stage disease 
(p = 0.02) originating in the oropharynx (p < 0.001), posi-
tive neck nodes, overexpression of p16 and positive HR-
HPV DNA status (p < 0.001). In contrast, tumours with 
predominantly ‘cytoplasmic’ EBP50 expression correlated 
with patients with a current smoking history, were local-
ised in the oral cavity and larynx, with no p16 overexpres-
sion and no positive nodes (p < 0.001).
No significant associations were found between EBP50 
staining patterns and grade of tumour differentiation, alco-
hol consumption, OS or recurrence. Patients with ‘weak/
negligible cytoplasmic’ EBP50 expression had the high-
est OS and RFS compared to those with ‘predominantly 
cytoplasmic’ EBP50 expression (OS—Median 49 months, 
50 vs. 68%; 5 years, 46 vs. 60%, P > 0.05; RFS—5 years, 
64 vs. 87%, P = 0.04) (data not shown). When the impact 
of clinical and histological variables on RFS was investi-
gated through univariate survival analysis, smoking status 
at diagnosis (P = 0.001), and EBP50 expression (P = 0.04) 
were found to be significantly associated with RFS.
In total, 40 samples were positive for HR-HPV DNA 
(25%) and 44 were p16 positive (28%). Of the HPV-posi-
tive samples, 39 were HPV16 positive and one was HPV18 
positive. From the anatomic breakdown, the majority of 
HPV-positive tumours (83%) arose in oropharyngeal sites, 
whilst 17% arose in the oral cavity/other sites (Table 4). 
For the purposes of this study, a specimen was HPV posi-
tive if it was both p16 and HPV DNA positive. To compare 
p16 and EBP50 expression as indicators of HPV infection, 
the relative strength of their dependence with HPV DNA 
status was tested. Two independent Pearson’s Chi Squared 
tests (χ2) were performed to test the dependence between 
EBP50 expression, HPV DNA status and p16 expression 
and HPV DNA status (Table 5). Each test showed a strong 
correlation between HPV DNA status and the indicator 
variables. Since the P values for both tests were identical 
(P < 0.001), the strength of goodness of fit of the variables 
was compared. The Likelihood Ratio for p16 status (87) 
was marginally higher than EBP50 expression (79.4).
Table 2  Summary of the 
immunohistochemical EBP50 
staining patterns found in 
HNSCC in a large Scottish 
cohort
The majority of tumours had cytoplasmic EBP50. In general, with the exception of a few minor examples, 
HNSCC samples were immunonegative for membranous EBP50
a In a few cells within the tumour
b Variation in EBP50 staining across a tumour (−/+, ++ or +++)
EBP50 staining Membrane staining Cytoplasmic staining No. of tumours %
Negligible/weak – −/+ 44 28
Moderate – ++ 76 49
Strong – +++ 5 3
Heterogeneous Tracesa Variableb 13 17
Heterogeneous – Variableb 13
Other Tracesa −/+, ++ 5 3
 Head and Neck Pathology
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Discussion
A number of studies have reported on the potential role of 
EBP50 in carcinogenesis, including breast [24, 25], liver [6], 
colorectal [5], and gastric cancers [19]. Here, we report for 
the first time a study on EBP50 expression, and the impact of 
HR-HPV on EBP50 expression in HNSCC tumours in order 
to establish its validity as a novel biomarker of HR-HPV 
infection in HNSCC.
Collectively, our data support a model whereby the level 
and subcellular distribution of EBP50 may determine its 
function, define distinct patient profiles and identify loss 
of EBP50 as a potential surrogate biomarker for HR-HPV 
infection in oropharyngeal tumours (Fig. 3). Cytoplasmic 
EBP50 was found in the stratum basale in normal tissue 
(Fig. 3b) and in the majority of tumours (Fig. 3c), consistent 
with a role in this predominantly proliferative pool of epithe-
lial cells [4, 25]. In contrast, membrane-associated EBP50 
was found in the suprabasal layers (Fig. 3a), but absent 
from the basal layer (Fig. 3b) and tumour sections (Fig. 3c), 
consistent with a role as a tumour suppressor. Contrary to 
others, we found no conclusive evidence for nuclear EBP50, 
which has been reported to regulate the Wnt/β-catenin path-
way [26, 27], and be a prognostic marker in breast cancer 
[28].
Two distinct patient profiles in this cohort were revealed 
when the relationship between EBP50 expression patterns 
and clinicopathologic characteristics was analysed, with 
significant associations noted with smoking history at 
diagnosis, site of primary tumour, disease stage, lymph 
node status, p16 status and HPV status (Fig. 3). The major-
ity of tumours with ‘predominantly cytoplasmic’ EBP50 
were more likely to be patients with a smoking history, 
with p16/HR-HPV-negative tumours arising in non-oro-
pharyngeal sites such as the oral cavity and larynx with no 
involvement of neck nodes (Fig. 3c). In contrast, patients 
who were either non-smokers or ex-smokers at the time 
of diagnosis, had p16/HR-HPV-positive oropharyngeal 
tumours, presented with positive neck nodes, late stage 
disease, and were more likely to have ‘weak/negligible 
Fig. 2  Cytoplasmic EBP50 
is primarily found in tumour 
tissue. Immunohistochemical 
examples of sections with (a) 
no primary antibody control, 
counterstained with haema-
toxylin, or (b) tumours having 
‘predominantly cytoplasmic’ or 
(d) ‘weak-negligible’ EBP50 
staining. ×100 magnification. 
Panels (c) and (e) are expanded 
sections from (b) and (d), 
showing cytoplasmic staining 
of EBP50, with no detectable 
membrane staining. Magnifica-
tion ×400
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Table 3  Social demographics and clinicopathological characteristics of patients based on EBP50 expression
Variable EBP50 expression patterns
Predominantly 
cytoplasmic
Weak/negligible 
cytoplasmic
Hetero-geneous Other Total Pearson’s χ2
History of smoking
 Non-smoker 9 (15%) 12 (32%) 5 (22%) 1 (11%) 27 P = 0.019
 Smoker 36 (60%) 8 (22%) 11 (48%) 6 (67%) 61
 Ex-smoker 15 (25%) 17 (46%) 7 (30%) 2 (22%) 41
 Total 60 37 23 9 129a
History of alcohol consumption
 Light–moderate drinker 33 (43%) 27 (61%) 12 (46%) 3 (30%) 75 P = 0.14 (NS)
 Heavy drinker 15 (20%) 7 (16%) 8 (31%) 5 (50%) 35
 Non-drinker 8 (10%) 2 (5%) 3 (12%) 0 (0%) 13
 Ex-heavy drinker 2 (3%) 0 (0%) 0 (0%) 1 (10%) 3
 Alcohol status unknown 18 (24%) 8 (18%) 3 (11%) 1 (10%) 30
 Total 76 44 26 10 156
Site of primary tumour
 Oral cavity 17 (22.4%) 5 (11%) 7 (27%) 1 (10%) 30 P < 0.001
 Oropharynx 17 (22.4%) 31 (71%) 9 (35%) 2 (20%) 59
 Larynx 23 (30%) 2 (4%) 7 (27%) 6 (60%) 38
 Other 19 (25%) 6 (14%) 3 (11%) 1 (10%) 29
 Total 76 44 26 10 156
Grade of differentiation
 Well differentiated 1 (1%) 0 (0%) 0 (0%) 0 (0%) 1 P = 0.243 (NS)
 Moderately differentiated 32 (44%) 7 (18%) 11 (44%) 2 (25%) 52
 Poorly differentiated 33 (45%) 26 (67%) 12 (48%) 6 (75%) 77
 Moderate–poorly differentiated 7 (10%) 6 (15%) 2 (8%) 0 (0%) 15
 Total 73 39 25 8 145a
Disease stage
 Stage I 13 (18%) 3 (7%) 4 (18%) 3 (30%) 23 P = 0.02
 Stage II 12 (17%) 1 (2%) 3 (13%) 2 (20%) 18
 Stage III 12 (17%) 4 (9%) 6 (26) 3 (30%) 25
 Stage IVA & IVB 33 (45%) 32 (73%) 9 (39%) 1 (10%) 75
 Unknown 2 (3%) 4 (9%) 1 (4%) 1 (10%) 8
 Total 72 44 23 10 149a
Neck node status
 Negative 43 (59%) 5 (11%) 14 (54%) 8 (80%) 70 P < 0.001
 Positive 30 (41%) 39 (89%) 12 (46%) 2 (20%) 83
 Total 73 44 26 10 153a
p16 status
 Positive 7 (9%) 32 (73%) 3 (11%) 2 (20%) 44 P < 0.001
 Negative 69 (91%) 12 (27%) 23 (89%) 8 (80%) 112
 Total 76 44 26 10 156
HPV status
 Positive 6 (9%) 29 (83%) 3 (12%) 1 (11%) 39c P < 0.001
 Negative 63 (91%) 6 (17%) 22 (88%) 8 (89%) 99
 Total 69 35 25 9 138b
OS
 Alive 31 (41%) 27 (61%) 15 (58%) 6 (60%) 79 P = 0.12 (NS)
 Dead 45 (59%) 17 (39%) 11 (42%) 4 (40%) 77
 Total 76 44 26 10 156
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cytoplasmic’ EBP50 expression (Fig. 3d), suggesting these 
may have a different pathology from those expressing ‘pre-
dominantly cytoplasmic’ EBP50. The improved survival 
in this cohort is in keeping with other published work 
in this area suggesting that although these patients have 
aggressive disease they respond well to treatment [13]. 
HR-HPV E6 oncoprotein has the potential to interact with 
and mediate the degradation of a subset of PDZ-containing 
cell polarity regulators including human Dlg [29, 30] and 
EBP50 [9], and specific subcellular pools of cell polarity 
proteins [31, 32]. Consequently, reduced EBP50 expres-
sion in the group of patients with oropharyngeal tumours 
may be a result of HR-HPV E6-mediated degradation of 
membrane pools of EBP50 (Fig. 3d), thereby disrupting 
cell polarity which is central to the control of cell prolif-
eration and cell survival [10].
The relationship between EBP50 expression as an 
independent variable and clinical outcomes of patients 
in the cohort showed that patients with ‘predominantly 
cytoplasmic’ EBP50 expression had the worst prognosis 
whilst reduced cytoplasmic EBP50 expression was associ-
ated with better OS and RFS. Previous reports on clinical 
outcomes and EBP50 expression are varied, seemingly 
linked to subcellular localisation of the protein [3]. In 
invasive breast carcinomas, cytoplasmic EBP50, high or 
low, did not correlate with OS or DFS [28]. Likewise, 
in gastric cancer no correlation was found between OS 
rates and EBP50 expression [19]. In our cohort, a marked 
improvement was observed in the DFS survival rates for 
the patients with ‘weak/negligible cytoplasmic’ EBP50-
expressing tumours, while the survival rate of patients with 
‘predominantly cytoplasmic’ EBP50 steadily declined over 
Table 3  (continued)
Variable EBP50 expression patterns
Predominantly 
cytoplasmic
Weak/negligible 
cytoplasmic
Hetero-geneous Other Total Pearson’s χ2
Recurrence
 Yes 18 (24%) 5 (11%) 1 (4%) 1 (10%) 25 P = 0.067 (NS)
 No 58 (76%) 39 (89%) 25 (96%) 9 (90%) 131
 Total 76 44 26 10 156
Significant associations were noted between EBP50 expression and smoking history, site of primary tumour, stage of disease, metastasis to cer-
vical lymph nodes, tumour p16 and HPV status
a Patients with missing or unavailable data were excluded from analysis
b Patients with ‘Equivocal’ HPV status were excluded from analysis
c EBP50 staining could not be determined in one HPV-positive specimen
Table 4  Summary of HPV-positive tumours by anatomic location in 
the head and neck
The majority of HPV-positive tumours (33/40; 83%) arose from the 
oropharynx with the tonsils and base of the tongue being the most 
common subsites of origin. An overwhelming majority of the HPV-
positive tumours were infected with high-risk type 16
Head and neck 
subsite group
Clinical anatomic 
location
No. of patients Type of 
high-risk 
HPV
Oral cavity Dorsum of tongue 1 HPV 16
Palate 1 HPV 16
Anterior 1/3 of tongue 1 HPV 16
Oropharynx Base of tongue 9 HPV 16
Tonsil 24 HPV 16
Other Unknown primary 1 HPV 16
Pharynx 1 HPV 16
Nares 1 HPV 16
Nasal cavity 1 HPV 18
Table 5  EBP50 expression and p16 status correlation with HPV DNA status using Pearson’s χ2 tests
Two independent Pearson’s χ2 tests showed strong correlation between HPV DNA status and both p16 overexpression and EBP50 expression 
pattern
HPV DNA status 
(n = 156)
p16 Overexpression P value and likeli-
hood ratio value
EBP50 expression P value and likelihood ratio value
Positive Negative Weak/negligible Other
Positive 39 (75%) 13 (25%) P < 0.001
87
38 (73%) 14 (9%) P < 0.001
79.4Negative 5 (5%) 99 (95%) 6 (6%) 98 (63%)
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time. Since DFS analysis was not statistically significant, 
EBP50 expression may not be a valuable indicator of prog-
nosis in patients with HNSCC.
The molecular mechanisms, which are known to regulate 
the subcellular localisation of EBP50 and as such its func-
tion, are varied, ranging from phosphorylation or interaction 
with ERM proteins [3]. Functionally, membrane-associated 
EBP50 has been shown to regulate the adherens junction 
proteins E-cadherin and β-catenin at the cell surface [8]. 
In addition, EBP50 regulates PTEN, a negative regulator 
of PI-3K/AKT signalling at both the membrane and in the 
cytoplasm [3, 7]. Although we cannot attribute a function 
with the redistribution of EBP50 to the cytoplasm in our 
cohort, collectively, our data are consistent with a tumour 
suppressor function at the cell membrane, and oncogenic 
function in the cytoplasm (Fig. 3), possibly by regulating the 
PI-3K/AKT/PTEN axis in the cytoplasm and Wnt/β-catenin 
signalling through the adherens junction proteins E-cadherin 
and β-catenin at the cell membrane [3, 7, 8].
Conclusion
In the majority of oral cancers, EBP50 expression was pre-
dominantly cytoplasmic. A smaller group of tumours, the 
majority involving the oropharynx, demonstrated reduced/
negligible cytoplasmic EBP50 expression, which strongly 
correlated with a positive HR-HPV status. These data sug-
gest that EBP50 may act as a tumour suppressor when local-
ised at the plasma membrane or act as an oncogene when 
relocalised to the cytoplasm or its expression is lost. In addi-
tion, since EBP50 expression differs between oropharyngeal 
and non-oropharyngeal tumours, this may be linked to its 
degradation by HR-HPV and as such, could serve as a sur-
rogate marker for HR-HPV.
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Fig. 3  Subcellular localisation 
and levels of EBP50 define 
a distinct patient profile in 
HNSCC and may determine its 
function. In normal epithe-
lium, EBP50 is present on the 
membrane (thick black line) in 
suprabasal layers (S. spinosum, 
S. granulosum) (a tumour sup-
pressor function), whilst in the 
basal layers (light shading), it is 
present in the cytoplasm (b pro-
liferative function). In diseased 
tissue, high levels of cytoplas-
mic EBP50 (darker shading) are 
predominantly found in non-
oropharyngeal HNSCC, whilst 
HR-HPV associated tumours, 
which are predominantly found 
in the oropharynx, have little or 
no EBP50
 Head and Neck Pathology
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